Advertisement

Translation of Radiopharmaceuticals from Bench to Bedside: Regulatory and Manufacturing Issues

  • F. F. (Russ) Knapp
  • Ashutosh Dash
Chapter

Abstract

Radiopharmaceuticals (RPhs) are unique pharmaceuticals which contain radioisotopes which emit ionizing radiation. Depending on the nature of the radioisotope and application, radiopharmaceuticals are used for diagnostic applications, using radioisotopes which emit photons which can be detected externally for diagnostic purposes. The second group of RPhs contains particle-emitting radioisotopes which are used as therapeutic tools for treating various diseases. In some case, the radionuclide can be administered in an ionic form directly, such as using 123I for thyroid imaging, 131I for thyroid therapy, and 89Sr+ for treatment of bone pain, as described in Chap. 12. Generally, however, radioisotopes are directly attached to pharmaceutical targeting agents which are then administered for various applications, as described in earlier chapters. In every case, RPhs must be manufactured, handled, dispensed, and administered under controlled conditions, which are regulated by the appropriate government agencies. RPhs are either manufactured or distributed in a ready-to-use form from a central commercial manufacturer or from a central radiopharmacy dispensing site or prepared locally in a hospital-based radiopharmacy from “cold kits” and often using radioisotopes available from radionuclide generators. In some cases, hospitals synthesize the necessary ligands (targeting compound) at the hospital radiopharmacy and also formulate the radiopharmaceuticals. In all cases, RPhs are required to be prepared in conformance with a legal framework that is suited for conventional drugs similar to those manufactured by large drug commercial companies. Regulatory procedures necessary to control the production, dispensing, and use of radiopharmaceuticals are primarily focused on production methods. Preparation and handling of RPhs involve adherence to regulations on radiation protection and are regulated by a number of generally federal/regional directives, regulations, and rules to ensure safety. Radiopharmaceuticals are thus prepared in hospital radiopharmacies, centralized radiopharmacies, nuclear centers and institutes, or by industrial manufacturers.

Keywords

Active Pharmaceutical Ingredient Good Manufacture Practice Nuclear Regulatory Commission Master Formula Terminal Sterilization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Bacher K, Thierens HM. Accurate dosimetry: an essential step towards good clinical practice in nuclear medicine. Nucl Med Commun. 2005;26(7):581–6.PubMedCrossRefGoogle Scholar
  2. Belanger AP, Byrne JF, Paolino JM, DeGrado TR. Use of pressure-hold test for sterilizing filter membrane integrity in radiopharmaceutical manufacturing. Nucl Med Biol. 2009;36(8):955–9.PubMedCrossRefGoogle Scholar
  3. Brown S, Baker MH. The sterility testing of dispensed radiopharmaceuticals. Nucl Med Commun. 1996;7(5):327–36.CrossRefGoogle Scholar
  4. Butler D. Translational research: crossing the valley of death. Nature. 2008;453:840–2.PubMedCrossRefGoogle Scholar
  5. Callahan RJ, Chilton HM, Ponto JA, Swanson DP, Royal HD, Bruce AD. Procedure guideline for the use of radiopharmaceuticals. J Nucl Med Technol. 2007;35(4):272–5.PubMedCrossRefGoogle Scholar
  6. Castronovo Jr FP. Audits of radiopharmaceutical formulations. Am J Hosp Pharm. 1992;49(3):584–90.PubMedGoogle Scholar
  7. Cervera-Padrell AE, Skovby T, Kiil S, Gani R, Gernaey KV. Active pharmaceutical ingredient (API) production involving continuous processes – a process system engineering (PSE)-assisted design framework. Eur J Pharm Biopharm. 2012;82(2):437–56.PubMedCrossRefGoogle Scholar
  8. Chen M, Rhodes BA, Larson SM, Wagner Jr HN. Sterility testing of radiopharmaceuticals. J Nucl Med. 1974;15(12):1142–4.PubMedGoogle Scholar
  9. Cohen Y. Views on quality tests of radiopharmaceuticals. J Radioanal Chem. 1975;26(2):317–25.CrossRefGoogle Scholar
  10. Cox JA, Hesslewood SR, Palmer AM. A mechanism for professional and organizational audit of radiopharmacy departments. Nucl Med Commun. 1994;15(11):890–8.PubMedCrossRefGoogle Scholar
  11. De Vos FJ, De Decker M, Dierckx RA. The good laboratory practice and good clinical practice requirements for the production of radiopharmaceuticals in clinical research. Nucl Med Commun. 2006;26(7):575–9.CrossRefGoogle Scholar
  12. Decristoforo C, Peñuelas I. Towards a harmonized radiopharmaceutical regulatory framework in Europe? Q J Nucl Med Mol Imaging. 2009;53(4):394–401.PubMedGoogle Scholar
  13. Decristoforo C, Elsing P, Faivre-Chauvet A, Farstad B, Meyer G, Mikolajczak R, Penuelas I, Unak P, Wester G. The specific case of radiopharmaceuticals and GMP – activities of the Radiopharmacy Committee. Eur J Nucl Med Mol Imaging. 2008;35(7):1400–1.PubMedCrossRefGoogle Scholar
  14. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov. 2004;3:417.PubMedCrossRefGoogle Scholar
  15. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol. 2007;25:209.PubMedCrossRefGoogle Scholar
  16. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2):151–85.PubMedCrossRefGoogle Scholar
  17. Duatti A, Bhonsle U. Strengthening radiopharmacy practice in IAEA Member States. Semin Nucl Med. 2013;43(3):188–94.PubMedCrossRefGoogle Scholar
  18. Eberlein U, Bröer JH, Vandevoorde C, Santos P, Bardiès M, Bacher K, Nosske D, Lassmann M. Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine – a review. Eur J Nucl Med Mol Imaging. 2011;38:2269–81.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Elliot AT, Hilditch TE, Murray T, McNutty H. The design and construction of a central radiopharmacy. Nucl Med Comm. 1993;14:328–34.CrossRefGoogle Scholar
  20. Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, Mikolajczak R, Westera G, Gmeiner-Stopar T, Decristoforo C. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37(5):1049–62.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Freudenberg LS, Beyer T. Subjective perception of radiation risk. J Nucl Med. 2011;52:29S–35.PubMedCrossRefGoogle Scholar
  22. Gnau TR, Maynard CD. Reducing the cost of nuclear medicine: sharing radiopharmaceuticals. Radiology. 1973;108(3):641–5.PubMedCrossRefGoogle Scholar
  23. Gouveia BG, Rijo P, Gonçalo TS, Reis CP. Good manufacturing practices for medicinal products for human use. J Pharm Bioall Sci. 2015;7:87–96.Google Scholar
  24. Hall JE. The promise of translational physiology. Am J Physiol. 2002;283(2):E193–4.Google Scholar
  25. Harapanhalli RS. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals. Semin Nucl Med. 2010;40(5):364–84.PubMedCrossRefGoogle Scholar
  26. Hayashi K, Douhara K, Kashino G. Evaluation of the bubble point test of a 0.22-μm membrane filter used for the sterilizing filtration of PET radiopharmaceuticals. Ann Nucl Med. 2014;28(6):586–92.PubMedCrossRefGoogle Scholar
  27. Heller SL. Radiation safety in the central radiopharmacy. Semin Nucl Med. 1996;26(2):107–18.PubMedCrossRefGoogle Scholar
  28. Herrling P. Patent sense. Nature. 2007;449:174–5.PubMedCrossRefGoogle Scholar
  29. Jornitz MW. Integrity testing. Adv Biochem Eng Biotechnol. 2001;98:143–80.CrossRefGoogle Scholar
  30. Khurshid SJ, Sadiq MZ. Quality assurance in nuclear medicine-biological quality control of radiopharmaceuticals. Pak J Pharm Sci. 1996;9(1):43–54.PubMedGoogle Scholar
  31. Kowalsky RJ. A basic overview of radiopharmaceuticals and their relationship to nuclear pharmacy practice. J Pharm Pract. 1989;2(3):139–47.CrossRefGoogle Scholar
  32. Kumar V, Sunder N, Potdar A. Critical factors in developing pharmaceutical formulations–an overview. Part 2. Pharm Technol. 1992;16:86–8.Google Scholar
  33. Lass P, Scheffler J. Undergraduate teaching of nuclear medicine in European universities. Eur J Nucl Med Mol Imaging. 2003;30(7):1018–23.PubMedCrossRefGoogle Scholar
  34. Lipsky MS, Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract. 2001;14(5):362–7.PubMedGoogle Scholar
  35. Norenberg JP, Petry NA, Schwarz S. Operation of a radiopharmacy for a clinical trial. Semin Nucl Med. 2010;40(5):347–56.PubMedCrossRefGoogle Scholar
  36. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006;41(3):206–12.PubMedCrossRefGoogle Scholar
  37. Nunn AD. The cost of bringing a radiopharmaceutical to the patient’s bedside. J Nucl Med. 2007;48:169.PubMedGoogle Scholar
  38. Otte A, Maier-Lenz Dierckx RA. Good clinical practice: historical background and key aspects. Nucl Med Commun. 2005;26(7):563–741.PubMedCrossRefGoogle Scholar
  39. Ramírez de Arellano I, Piera C, Pavia J, Setoain J. Experiences in setting up the first centralized radiopharmacy in Spain. Nucl Med Commun. 1999;20(3):279–85.PubMedCrossRefGoogle Scholar
  40. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov. 2003;2:695.PubMedCrossRefGoogle Scholar
  41. Schelbert HR. Nuclear medicine at a crossroad. J Nucl Med. 2011;52:10S–5.PubMedCrossRefGoogle Scholar
  42. Seddon BM, Workman P. The role of functional and molecular imaging in cancer drug discovery and development. Br J Radiol. 2003;76(Spec No 2):S128.PubMedCrossRefGoogle Scholar
  43. Wang SC. Nuclear medicine training in china. Eur J Nucl Med. 1996;10:1405–7.CrossRefGoogle Scholar
  44. Woldring MG. Radiopharmaceuticals and good radiopharmacy practice. Pharm Weekblad Sci Ed. 1999;3(1):1285–301.Google Scholar
  45. Zigler SS. Instrumentation and radiopharmaceutical validation. Q J Nucl Med Mol Imaging. 2009;53(4):402–10.PubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  • F. F. (Russ) Knapp
    • 1
  • Ashutosh Dash
    • 2
  1. 1.Nuclear Security and Isotope DivisionOak Ridge National LaboratoryOAK RIDGEUSA
  2. 2.Isotope Production and Applications DivisionBhabha Atomic Research CentreMumbaiIndia

Personalised recommendations